FDA says biopsy needle too large for lumpectomy:
This article was originally published in Clinica
Executive Summary
An FDA advisory panel said last week that there is no scientific evidence to suggest that two devices used for breast biopsies should also be marketed for lumpectomy. The two devices, US Surgical's ABBI and Biopsys Medical Mammotome, use larger needles than other biopsy devices, and thus take more tissue. In June, the FDA issued a warning letter to US Surgical to stop marketing its device for lumpectomy. The General and Plastic Surgery Devices panel also said the agency should restrict the product's use in breast biopsies in those cases that are difficult to diagnose.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.